ASCO: Vorasidenib shows its glioma potential in INDIGO

Servier’s vorasidenib has shown efficacy in the treatment of low-grade glioma – a notoriously hard-to-treat form of brain cancer – although safety data has taken some of t

Servier’s $1.8bn Agios deal delivers glioma prospect

IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.

First launch for Daiichi Sankyo's oncolytic virus Delytact i...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer.

Merck KGaA offloads failed MEK programme to startup Day One

US biotech Day One has taken ownership of a cancer drug that has been languishing in Merck KGaA’s pipeline for years, in the hope of giving it a new lease of life. 

Agios up as FDA gives Thermo Fisher glioma test breakthrough...

Shares in Agios Pharma ticked upwards after the FDA awarded breakthrough status to a companion diagnostic to vorasidenib, its experimental drug for brain cancer.

Tocagen plummets on phase 3 data for glioma therapy